Joya Chandra
University of Texas MD Anderson Cancer Center
107 Papers
872 Citations
Joya Chandra is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Apoptosis & Medicine. The author has an hindex of 33, co-authored 104 publications. Previous affiliations of Joya Chandra include University of Rochester & University of Texas Health Science Center at Houston.
Chat about Author
Papers
Triggering and modulation of apoptosis by oxidative stress.
TL;DR: This review will address some of the current paradigms for oxidative stress and apoptosis, and discuss the potential mechanisms by which oxidants can modulate the apoptotic pathway.
1.4K
Cloning and Expression of a Novel Human Glutaredoxin (Grx2) with Mitochondrial and Nuclear Isoforms
Mathias Lundberg,Catrine Johansson,Joya Chandra,Mari Enoksson,Gunilla Jacobsson,Johanna Ljung,Magnus Johansson,Arne Holmgren +7 more
TL;DR: Western blot analysis of subcellular fractions from Jurkat cells with a specific anti-Grx2 antibody showed that human Grx2 was predominantly located in the nucleus but also present in the mitochondria, and it was shown that one of the mRNA isoforms corresponding to GrX2a encoded a functional N-terminal mitochondrial translocation signal.
354
Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Barbara C. M. Potts,M. X. Albitar,KC Anderson,Stavroula Baritaki,Celia R. Berkers,Ben Bonavida,Joya Chandra,D Chauhan,James C. Cusack,William Fenical,Irene M. Ghobrial,Michael Groll,Paul R. Jensen,Kin S. Lam,G. K. Lloyd,William H. McBride,David J. McConkey,Claudia P. Miller,Saskia T. C. Neuteboom,Y. Oki,Huib Ovaa,Frank Pajonk,Paul G. Richardson,Aldo M. Roccaro,Callum M. Sloss,Matthew A. Spear,E. Valashi,Anas Younes,Michael A. Palladino +28 more
TL;DR: This review captures the remarkable translational studies and contributions from many collaborators that have advanced marizomib from seabed to bench to bedside.
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells
Claudia P. Miller,Kechen Ban,Melanie E. Dujka,David J. McConkey,Mark F. Munsell,Michael A. Palladino,Joya Chandra +6 more
TL;DR: Effects of NPI-0052, a novel proteasome inhibitor, in leukemia model systems are described and further testing is warranted to determine the compound's clinical efficacy in leukemia.
215
Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis
Leta K. Nutt,Joya Chandra,Abujiang Pataer,Bingliang Fang,Jack A. Roth,Stephen G. Swisher,Roger G. O'Neil,David J. McConkey +7 more
TL;DR: The data demonstrate that Bax-mediated alterations in ER and mitochondrial Ca2+ levels serve as important upstream signals for cytochrome c release in some examples of apoptosis.
211